Organogenesis Statistics
Share Statistics
Organogenesis has 126.85M
shares outstanding. The number of shares has increased by -4.33%
in one year.
| Shares Outstanding | 126.85M |
| Shares Change (YoY) | -4.33% |
| Shares Change (QoQ) | 0.88% |
| Owned by Institutions (%) | 47.17% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,369 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 11.77M, so 9.28% of the outstanding
shares have been sold short.
| Short Interest | 11.77M |
| Short % of Shares Out | 9.28% |
| Short % of Float | 15.12% |
| Short Ratio (days to cover) | 7.16 |
Valuation Ratios
The PE ratio is 489.38 and the forward
PE ratio is 15.97.
Organogenesis's PEG ratio is
-3.87.
| PE Ratio | 489.38 |
| Forward PE | 15.97 |
| PS Ratio | 0.87 |
| Forward PS | 0.6 |
| PB Ratio | 1.09 |
| P/FCF Ratio | 100.9 |
| PEG Ratio | -3.87 |
Financial Ratio HistoryEnterprise Valuation
Organogenesis has an Enterprise Value (EV) of 329.1M.
| EV / Sales | 0.68 |
| EV / EBITDA | 20.88 |
| EV / EBIT | 23.16 |
| EV / FCF | 78.81 |
Financial Position
The company has a current ratio of 3.69,
with a Debt / Equity ratio of 0.11.
| Current Ratio | 3.69 |
| Quick Ratio | 3.35 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 2.75 |
| Debt / FCF | 10.37 |
| Interest Coverage | -0.83 |
Financial Efficiency
Return on Equity is 0.22% and Return on Invested Capital is 0.09%.
| Return on Equity | 0.22% |
| Return on Assets | 0.17% |
| Return on Invested Capital | 0.09% |
| Revenue Per Employee | $554,710.01 |
| Profits Per Employee | $990.79 |
| Employee Count | 869 |
| Asset Turnover | 0.97 |
| Inventory Turnover | 4.41 |
Taxes
| Income Tax | -3.67M |
| Effective Tax Rate | 130.67% |
Stock Price Statistics
The stock price has increased by 13.14% in the
last 52 weeks. The beta is 1.85, so Organogenesis's
price volatility has been higher than the market average.
| Beta | 1.85 |
| 52-Week Price Change | 13.14% |
| 50-Day Moving Average | 4.48 |
| 200-Day Moving Average | 3.57 |
| Relative Strength Index (RSI) | 32.17 |
| Average Volume (20 Days) | 2,523,935 |
Income Statement
In the last 12 months, Organogenesis had revenue of 482.04M
and earned 861K
in profits. Earnings per share was -0.01.
| Revenue | 482.04M |
| Gross Profit | 366.3M |
| Operating Income | -1.28M |
| Net Income | 861K |
| EBITDA | 15.76M |
| EBIT | -1.26M |
| Earnings Per Share (EPS) | -0.01 |
Full Income StatementBalance Sheet
The company has 135.57M in cash and 43.31M in
debt, giving a net cash position of 92.26M.
| Cash & Cash Equivalents | 135.57M |
| Total Debt | 43.31M |
| Net Cash | 92.26M |
| Retained Earnings | -40.11M |
| Total Assets | 467.39M |
| Working Capital | 203.11M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 14.21M
and capital expenditures -10.03M, giving a free cash flow of 4.18M.
| Operating Cash Flow | 14.21M |
| Capital Expenditures | -10.03M |
| Free Cash Flow | 4.18M |
| FCF Per Share | 0.03 |
Full Cash Flow StatementMargins
Gross margin is 75.99%, with operating and profit margins of -0.27% and 0.18%.
| Gross Margin | 75.99% |
| Operating Margin | -0.27% |
| Pretax Margin | -0.58% |
| Profit Margin | 0.18% |
| EBITDA Margin | 3.27% |
| EBIT Margin | -0.27% |
| FCF Margin | 0.87% |
